Dr. Lin on Impact of Neratinib on CNS Metastases in HER2+ Breast Cancer

Video

Nancy Lin, MD, discusses the impact of neratinib on development and progression of central nervous system metastases in patients with HER2-positive metastatic breast cancer.

Nancy Lin, MD, discusses the impact of neratinib (Nerlynx) on development and progression of central nervous system (CNS) metastases in patients with HER2-positive metastatic breast cancer.

This analysis presented at the 2019 San Antonio Breast Cancer Symposium pulled together CNS data from the NALA, NEfERT-T, and TBCRC 022 trials, explains Lin. The phase III NALA trial comparing lapatinib (Tykerb) plus capecitabine versus neratinib plus capecitabine in patients with HER2-positive, pretreated, metastatic breast cancer. The NEfERT-T trial compared first-line neratinib plus paclitaxel versus trastuzumab paclitaxel in HER2-positive metastatic breast cancer. Finally, the TBCRC 022 trial was a single-arm multi-cohort study specifically enrolling patients with progressive CNS disease. In that study, the primary endpoint was CNS objective response.

The goal of analyzing the data from these 3 trials was to compile the CNS-focused data in 1 place, focusing on CNS progression and response, concludes Lin.

<<< View more from 2019 San Antonio Breast Cancer Symposium

Related Videos
Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD
Reshma Lillaney Mahtani, DO
Patrick I. Borgen, MD
Kari Hacker, MD, PhD, NYU Grossman School of Medicine
Janos L. Tanyi, MD, PhD, associate professor, Obstetrics and Gynecology, Hospital of the University of Pennsylvania
Reshma Lillaney Mahtani, DO
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital